Following the largest dealmaking quarter in six years, PwC analysts have empirically stated that the biopharma ecosystem is “back to full health”.
In its midyear outlook report, the firm stated that US pharma and life sciences deal value in Q1 2026 surpassed $65bn, marking the strongest quarter since pandemic-related highs in 2020. PwC’s analysts state this was buoyed by a surge in deals surpassing the billion-dollar ceiling as pharma companies look to differentiate their pipelines with modalities such as glucagon-like peptide-1 receptor agonists (GLP-1RAs), RNA therapeutics, and antibody-drug conjugates (ADCs).
According to the PwC team, the main driver behind this surge is the ongoing patent cliff – the largest loss of exclusivity (LOE) off-ramps ever to hit the industry. According to GlobalData, the share of global drug sales under patent protection will only be 4% in 2030, compared to 12% in 2022.
PwC puts the amount of branded pharma revenue exposed at more than $300bn, forcing pharma companies either to accelerate in-house R&D or look elsewhere for pipeline additions.
The firm’s analysts comment that focused and bespoke mid-cap biotech and bolt-on transactions “remain the sweet spot” for the biopharma M&A market.
No drugmaker has perhaps encapsulated this idea more so far this year than Eli Lilly. With healthy amounts of cash at hand courtesy of burgeoning sales for its weight loss drugs, Lilly has undertaken an extensive M&A strategy in 2026. In total, the company has so far bought 10 companies this year. The most expensive of these was the $7.8bn deal to buy sleep drug biotech Centessa at the beginning of January.
In a statement to Pharmaceutical Technology, Roel van den Akker, principal US pharmaceutical & life sciences deals leader at PwC, said: “After a strong start to the year, the outlook for pharmaceutical and life sciences dealmaking remains positive. The combination of patent-expiration pressures, demand for differentiated innovation and healthy capital availability is creating a favorable environment for transactions.
"In tandem, the pace of scientific advancement continues to accelerate across areas such as oncology, immunology and next-generation therapeutics, increasing the need for companies to access breakthrough innovation through acquisitions, licensing agreements and strategic partnerships. As companies look to accelerate growth and strengthen their competitive positions, we expect M&A activity to remain an important strategic priority through the remainder of 2026."
The resurgence of the biopharma industry’s financial side comes despite upheaval in geopolitical arenas. Most Favored Nation (MFN) drug pricing frameworks, tariff threats on pharmaceutical imports, and Inflation Reduction Act (IRA) negotiation expansions are all shaping transaction strategy.
Q2 follows suit as biopharma optimism rises
PwC’s report only analyses Q1, but Q2 showcases that M&A momentum is showing no signs of slowing. The two largest deals in pharma came in the latter quarter – Sun Pharma’s $11.75bn takeover of Organon and GSK’s $10.6bn acquisition of cancer specialist Nuvalent in April and June, respectively.
For the year ahead, the team outlines that urgency to bolster pipelines will remain a key driver.
“Large-cap pharma is likely to remain in active portfolio-replenishment mode. Deal activity continues to concentrate around high-growth, strong-margin therapeutic areas – cardiometabolic and obesity, immunology and inflammation, oncology, and rare disease – while radiopharmaceuticals and RNA medicines also continue to command a premium.”
A GlobalData survey of pharmaceutical industry professionals concurs with this optimism. In its State of the Biopharmaceutical Industry 2026 (Mid-Year Update Edition) report, data reflects a positive industry sentiment – 55% of respondents were optimistic or very optimistic about the next year for biopharma.
“Even with lingering policy and geopolitical risks, respondents’ optimism is underpinned by the sector’s innovation and capital formation,” the report stated.
According to GlobalData, dealmaking volume is evidence of this confidence. The report details how large-cap pharma companies are using strong balance sheets to secure late-stage programmes in a race to beat the patent cliff. Assets targeted are those that can move quickly and materially de-risk revenue gaps.
IPO window reopens
The uptick in M&A has also gone hand-in-hand with a resurgent initial public offering (IPO) window. Earlier this month, Parabilis Medicines secured the largest IPO in biotech history when it listed on the Nasdaq with $670m in proceeds. Parabilis’ IPO came just two months after Kailera Therapeutics – a biotech developing obesity therapies – secured $625m in a US listing. At the time, this was the largest IPO in biotech history, meaning the record has been broken twice in as many months.
PwC analysts said that tighter exit strategies for biotechs still exist, which will continue to be a factor in M&A for the rest of the year.
“While the biotech IPO window is slowly opening again, there are still only a small number of companies making their debut on the public market. IPOs are requiring increased proof of clinical success, making many biotechs seek alternative exits,” the report says.
However, the report states that those who have made the public jump are doing well with favourable valuations, signalling renewed investor confidence. The influx of capital, too, is helping propel pipelines towards late-stage development.
According to GlobalData's mid-year report: "The shift towards later-stage M&As has boosted the IPO market, as big pharma seeks strategic acquisitions to refuel its pipelines ahead of upcoming patent expiries. Some biotech companies could turn to M&As as an alternative exit strategy."
Editor's note: This article was updated on 18 June to include data from GlobalData's State of the Biopharmaceutical Industry 2026 Mid-Year report – paragraphs 13, 14, 15, and 20 have been updated.
